Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyTumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionClinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.The role of primary pharmacological therapy in acromegaly.Pharmacokinetic evaluation of lanreotide.Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsManagement options for persistent postoperative acromegaly.Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Adverse events associated with somatostatin analogs in acromegaly.The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis.Management of hormone-secreting pituitary adenomas.Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.Multi-modal management of acromegaly: a value perspective.Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects.
P2860
Q26777682-5BAA2CE9-5271-409D-97FB-F320ADC7E33AQ33564399-3851AA9F-1E9F-4D56-B295-93B3B66EBAA7Q33595081-BC0CACE5-4985-4712-8017-62E12D8CDC2FQ33772673-82AE84A3-BADE-4263-BB9B-F1EBEB8DBB07Q35977997-9E1BFAE7-45A0-41A7-BD0D-6F3820036BBDQ37519612-E9206DEE-64F9-4574-996B-05C0ACA51096Q37531005-4D44B946-B6FA-4C7D-A7B6-CF01503CAB40Q37780553-0865D853-5FE9-45E3-B5C2-E4E845A74C3BQ37941521-C0F161C8-0EE1-47FF-AFEA-F15BBB853961Q37980741-811C68FB-28A5-4B66-960A-953F9570D41FQ38049832-91255267-DEC0-4959-90F3-28AF7E97C483Q38073189-19CC92E3-40E2-48E6-8D19-D60F429E87C4Q38246440-B582B267-5D9F-448E-BB30-42BE6186444AQ38259409-AC27E44B-1FDE-420E-B3DD-999121221D50Q38373377-84BAAEFD-8CA6-490C-836C-338FC5BB83D0Q38548973-6B4B0CE7-9AE6-48C8-83A2-62D5CB54CB61Q38862772-65F76828-F85E-4CE2-8D8F-15672FA6D04CQ39168432-9353E905-E4E9-4C25-967B-A1B3429D17C3Q39687911-F711CDC4-FB47-45A6-8FDD-F2E499A18DE5Q41627761-866EB640-CEE0-4E2F-B0A3-503DCB651B2DQ42378746-65D1C810-D19F-4A00-A293-EFC6C63ACABEQ43078115-CF66836A-DD8B-4B38-8A18-0A5E355C188CQ51374477-9A53FA91-B5EA-4F2B-AF3B-5B6EE2063EB8Q51571230-5ACCF2F1-75B0-4A29-827C-4BB1A6E8B60FQ51766789-F85676F4-6006-4682-B7C0-6BD9EE559F30
P2860
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Control of IGF-I levels with t ...... s in patients with acromegaly.
@en
Control of IGF-I levels with t ...... s in patients with acromegaly.
@nl
type
label
Control of IGF-I levels with t ...... s in patients with acromegaly.
@en
Control of IGF-I levels with t ...... s in patients with acromegaly.
@nl
prefLabel
Control of IGF-I levels with t ...... s in patients with acromegaly.
@en
Control of IGF-I levels with t ...... s in patients with acromegaly.
@nl
P2093
P2860
P1476
Control of IGF-I levels with t ...... s in patients with acromegaly.
@en
P2093
Brigitte Delemer
Jean-Marc Kuhn
Joëlle Blumberg
Lanreotide Acromegaly Study Group
Pascal Maisonobe
Philippe Chanson
P2860
P304
P356
10.1111/J.1365-2265.2008.03208.X
P577
2008-01-31T00:00:00Z